Corrigendum to ‘Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958–1971](S0149291814005517)(10.1016/j.clinthera.2014.08.013);Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: An integrated analysis of the phase 3 DEFINE and CONFIRM studies

Clinical Therapeutics

Volumn 36, Issue 12, 2014, Pages 1958-1971

  Kita, Mariko ^a   Fox, Robert J ^b   Gold, Ralf ^c   Giovannoni, Gavin ^d   Phillips, J Theodore ^e   Sarda, Sujata P ^f   Kong, Jessica ^f   Viglietta, Vissia ^f   Sheikh, Sarah I ^f   Okwuokenye, MacAulay ^f   Kappos, Ludwig ^g  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c ST JOSEF HOSPITAL   (Germany)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^f BIOGEN   (United States)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

delayed release dimethyl fumarate; multiple sclerosis; quality of life; randomized controlled trial

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; DELAYED RELEASE FORMULATION; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; EUROQUALITY OF LIFE 5D; EXPANDED DISABILITY STATUS SCALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MENTAL COMPONENT SUMMARY; MENTAL HEALTH; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PHYSICAL COMPONENT SUMMARY; PHYSICAL DISABILITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SENSITIVITY ANALYSIS; SHORT FORM 36; SOCIAL INTERACTION; VISUAL ANALOG SCALE; WELLBEING; ADMINISTRATION AND DOSAGE; ADOLESCENT; FEMALE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PAIN MEASUREMENT; THERAPEUTIC USE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; DELAYED-ACTION PREPARATIONS; DIMETHYL FUMARATE; FEMALE; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PAIN MEASUREMENT; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84916931012     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2018.02.005     Document Type: Erratum

References (25)

1. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status. Qual Life Res. 2006;15:259-271.
2. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler. 2003;9: 63-72.
3. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367: 1098-1107.
4. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl JMed. 2012;367:1087-1097. Erratum in: N Engl J Med. 2012;367:1673.
5. Ware JE. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25: 3130-3139.
6. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
7. Kappos L, Gold R, Arnold DL, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler. 2014;20:243-252.
8. Kita M, Fox RJ, Phillips JT, et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler. 2014;20:253-257.
9. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58:840-846.
10. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. Cary, NC, USA: SAS Institute and Wiley; 2000.
11. Jongen PJ, Sindic C, Carton H, et al. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J Neurol. 2010;257:584-589.
12. Jongen PJ, Lehnick D, Sanders E, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multicentre study. Health Qual Life Outcomes. 2010;8:133.
13. Lily O, McFadden E, Hensor E, et al. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler. 2006;12:808-813.
14. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62:335-346.
15. Miller DM, Weinstock-Guttman B, Bourdette D, et al. Change in quality of life in patients with relapsingremitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a. Mult Scler. 2011;17:734-742.
16. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to diseasemodifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69-77.
17. de Seze J, Borgel F, Brudon F. Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence. 2012;6:263-273.
18. Bar-Or A, Gold R, Fox R, et al. Clinical efficacy and safety of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis (RRMS): an integrated analysis of the phase 3 DEFINE and CONFIRM studies. 7th Latin-American Congress of Multiple Sclerosis. Rio de Janeiro, Brazil, 2012.
19. Hobart J, Freeman J, Lamping D, et al. The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry. 2001;71:363-370.
20. Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care. 2000;38:115-121.
21. Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care. 2005; 43:1078-1086.
22. Macran S, Weatherly H, Kind P. Measuring population health: a comparison of three generic health status measures. Med Care. 2003;41:218-231.
23. Fisk JD, Brown MG, Sketris IS, et al. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry. 2005;76:58-63.
24. Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes. Diabet Med. 2009;26:315-327.
25. Menn P, Weber N, Holle R. Healthrelated quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes. 2010;8:39.